CC-5013 (Lenalidomide)

CC-5013 (Lenalidomide) is an inhibitor of TNF-alpha and E3 Ligase used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. It is especially relevant in apoptosis, cancer, and immunology models, where defined compound exposure can be linked to inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses.

By inhibiting TNF-alpha and E3 Ligase, CC-5013 (Lenalidomide) can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The immunomodulator annotation adds relevance to immune-cell activation, cytokine, and mediator assays, together with downstream-response mapping in the same experimental setting. In apoptosis, cancer, and immunology models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving TNF-alpha and E3 Ligase
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Immune-cell activation, cytokine, and mediator assays

Overall, CC-5013 (Lenalidomide) is appropriate when a defined chemical perturbant is needed to connect TNF-alpha and E3 Ligase with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, cancer, and immunology models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.